<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05075850</url>
  </required_header>
  <id_info>
    <org_study_id>PENSAR LAANTERN Registry</org_study_id>
    <nct_id>NCT05075850</nct_id>
  </id_info>
  <brief_title>Multicenter Sub-study for LAANTERN Registry NCT02392078 That Will Include Comprehensive Neuropsychological Assessment Data Collection</brief_title>
  <official_title>PatiEnt Neuropsychological outcomeS After laseR Ablation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Monteris Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Monteris Medical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      PatiEnt Neuropsychological outcomeS After laseR ablation&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter sub-study that will include comprehensive neuropsychological assessment&#xD;
      data collection done at baseline (within 1 year prior to the index LITT procedure) and at&#xD;
      follow-up (at least 6 months from the index LITT procedure). Visual field testing will be&#xD;
      conducted in a subset of enrolled patients. Up to 250 subjects may be enrolled at up to 15&#xD;
      study sites.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 29, 2021</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>Site-determined cognitive changes per domain</measure>
    <time_frame>At least six months from baseline assessment</time_frame>
    <description>Neuropsychological test data will be collected for all study participants to describe cognitive domain specific changes as a cohort. Change will be assessed from raw test scores and demographically corrected standardized scores (where available). For this study, collected cognitive domains include Language, Executive Function, Attention, Verbal Memory, Visual Memory, Verbal Fluency, and Motor Function.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in raw test scores from standard battery of preferred neuropsychological tests</measure>
    <time_frame>At least six months from baseline assessment</time_frame>
    <description>Describe the observed change or stability of neuropsychological test scores in patients who underwent laser ablation surgery. Change will be assessed from raw test scores and demographically corrected standardized scores (where available). For this study, tests include Boston Naming, Trails making Test A and Test B, Digit Span, Logical memory test (subtest from Wechsler Memory Scale IV), BVMT--Brief Visuospatial Memory Test, Animal Fluency test, and Grooved Pegboard.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of visual field deficits in patients with MTLE</measure>
    <time_frame>At least six months from baseline assessment</time_frame>
    <description>Visual field testing using Humphry automated fields (HVF 24-2 SITA standard) will be conducted for a subset of patients to identify visual field deficits resulting after the LITT procedure.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Cognitive Change</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Neuroblate System</intervention_name>
    <description>All subjects will undergo comprehensive neuropsychological assessment post-LITT per standard of care practice.&#xD;
Visual field testing will be conducted in a subset of enrolled patients.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        This study is being conducted as a sub-study within the LAANTERN registry; therefore, all&#xD;
        enrolled patients in PENSAR must be consented to both protocols.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient or legally authorized representative provides written authorization and/or&#xD;
             consent.&#xD;
&#xD;
          2. Patient is enrolled in the LAANTERN trial and had an epilepsy diagnosis without the&#xD;
             presence of a malignant brain tumor.&#xD;
&#xD;
          3. Patient is 16 years of age or older.&#xD;
&#xD;
          4. Patient has completed a baseline comprehensive neuropsychological assessment with a&#xD;
             neuropsychologist.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        1. Patient does not complete the index LITT procedure as specified in the LAANTERN&#xD;
        registry.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Laura Menck</last_name>
    <phone>6127990288</phone>
    <email>lmenck@monteris.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lauren Holland</last_name>
      <email>lholland2@kumc.edu</email>
    </contact>
    <investigator>
      <last_name>Patrick Landazuri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 15, 2021</study_first_submitted>
  <study_first_submitted_qc>October 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 13, 2021</study_first_posted>
  <last_update_submitted>October 8, 2021</last_update_submitted>
  <last_update_submitted_qc>October 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Quality of Life</keyword>
  <keyword>Neuropsychological Test Scores</keyword>
  <keyword>Visual Field</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

